Item 8.01 Other Events.
On January 13, 2021, Inhibrx, Inc. (the "Company") issued a press release
announcing the U.S. Food and Drug Administration has granted Fast Track
designation to INBRX-109 for the treatment of patients with unresectable or
metastatic conventional chondrosarcoma. INBRX-109 is a precisely engineered
tetravalent single domain antibody-based therapeutic candidate that agonizes
death receptor 5 (DR5) to induce tumor selective programmed cell death.
The full text of the Company's press release regarding this announcement is
filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein
by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release issued by Inhibrx, Inc. on January 13, 2021
© Edgar Online, source Glimpses